Patent · US Active

Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)

US8481030B2 · kind B2 · utility

7Cited by

8References

6Claims

0Family size

Assignee

BAYER HEALTHCARE LLC · DE

Inventors

Zhuozhi Wang · Millbrae, US
Junliang Pan · Moraga, US
Joanna Grudzinska · Cologne, DE
Christian Votsmeier · Cologne, DE
Jan Tebbe · Cologne, DE
Joerg Birkenfeld · Frankfurt am Main, DE
Nina Wobst · Wuppertal, DE
Simone Brueckner · Cologne, DE
Susanne Steinig · Cologne, DE
Peter Scholz · Cologne, DE

Key dates

Filing date	Dec 12, 2011
Grant date	Jul 9, 2013
Priority date	—
Expiry date	Dec 12, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/21
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.